Szeliski Kamil, Fekner Zuzanna, Kasiński Damian, Rasmus Marta, Kowalski Filip, Świtońska Milena, Sierakowska Katarzyna, Drewa Tomasz, Pokrywczyńska Marta
Chair of Urology and Andrology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Chair of Urology and Andrology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Nanomedicine. 2025 Jul;67:102828. doi: 10.1016/j.nano.2025.102828. Epub 2025 May 11.
Diagnosing prostate cancer (PCa) and risk-stratifying patients remains challenging, as PSA-based methods lack precision for active surveillance (AS) decision-making. Extracellular vesicles (EVs) are membranous nano-sized vesicles released by all types of cells and may contain potentially interesting material for diagnostic procedures for PCa. This study analyzed surface markers and miRNA profiles of medium-sized plasma EVs (mEVs) from 24 PCa patients using nanoflow cytometry and miRNA profiling. The ratio of PSMA+ EVs to PSMA+CD9+ EVs differed significantly between AS and non-AS patients. Additionally, miR-99a-5p, miR-125b-5p, miR-145-5p, and miR-365a-3p levels were higher in non-AS patients. These findings suggest that plasma-derived PSMA+ mEVs originate from the prostate and may serve as biomarkers for PCa progression. Nanoflow cytometry-based analysis of EV surface markers combined with miRNA profiling provides a novel, non-invasive alternative to PSA measurements. This approach could improve risk stratification and decision-making for AS patients, potentially leading to better outcomes.
诊断前列腺癌（PCa）并对患者进行风险分层仍然具有挑战性，因为基于前列腺特异性抗原（PSA）的方法在用于主动监测（AS）决策时缺乏精准性。细胞外囊泡（EVs）是由所有类型细胞释放的膜性纳米级囊泡，可能含有对PCa诊断程序具有潜在价值的物质。本研究使用纳流细胞术和微小RNA（miRNA）分析，对24例PCa患者的中等大小血浆细胞外囊泡（mEVs）的表面标志物和miRNA谱进行了分析。AS患者与非AS患者之间，前列腺特异性膜抗原（PSMA）阳性的EVs与PSMA阳性且CD9阳性的EVs的比例存在显著差异。此外，非AS患者中miR-99a-5p、miR-125b-5p、miR-145-5p和miR-365a-3p的水平更高。这些发现表明，血浆来源的PSMA阳性mEVs起源于前列腺，可能作为PCa进展的生物标志物。基于纳流细胞术的EV表面标志物分析与miRNA分析相结合，为PSA测量提供了一种新的非侵入性替代方法。这种方法可以改善AS患者的风险分层和决策，可能带来更好的结果。
